Cerevel Therapeutics' Tavapadon Shows Promise in Phase 3 Trial for Parkinson's Disease, Suppliers' Revenues Decline but Sequential Sales and Profit Margins Improve.
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson s DiseaseCerevel Therapeutics, a biopharmaceutical company focused on developing therapi...
Apr 18, 2024
• Major Pharmaceutical Preparations Industry
Clinical Study
